Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:FRENASDAQ:GNFT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFREFremont GoldC$0.15C$0.15C$0.05▼C$0.17C$8.71M0.4340,741 shs28,000 shsGNFTGENFIT$3.61-6.0%$4.11$2.55▼$6.42$180.50M1.1510,510 shs22,737 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFREFremont Gold0.00%0.00%0.00%0.00%+76.47%GNFTGENFIT0.00%-7.08%-17.58%+5.56%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFREFremont Gold0.847 of 5 stars2.00.01.70.01.11.70.0GNFTGENFIT2.2352 of 5 stars3.54.00.00.02.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFREFremont Gold 0.00N/AC$16.5010,900.00% UpsideGNFTGENFIT 3.00Buy$13.00260.11% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFREFremont GoldN/AN/AC$0.08 per share1.84C$0.00 per shareN/AGNFTGENFIT$76.77M2.35$0.07 per share51.61$1.50 per share2.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFREFremont Gold-C$6.24M-C$0.11N/A∞N/AN/A-378.07%-104.83%N/AGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFREFremont GoldN/A12.12%N/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFREFremont GoldN/A0.831.79GNFTGENFIT0.081.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFREFremont Gold0.69%GNFTGENFIT2.24%Insider OwnershipCompanyInsider OwnershipFREFremont Gold22.50%GNFTGENFIT4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFREFremont GoldN/A58.07 millionN/ANot OptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableFRE, EI, and GNFT HeadlinesRecent News About These CompaniesGENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) Short Interest Down 25.7% in MayJune 18, 2025 | marketbeat.comGENFIT: June 17, 2025 Combined Shareholders Meeting ResultsJune 17, 2025 | globenewswire.comMillennium Management LLC Invests $611,000 in Genfit S.A. (NASDAQ:GNFT)June 8, 2025 | marketbeat.comGenfit S.A. (NASDAQ:GNFT) Short Interest Down 23.0% in MayJune 3, 2025 | marketbeat.comGenfit (NASDAQ:GNFT) Stock Price Up 0.5% - Here's WhyMay 30, 2025 | marketbeat.comGENFIT S.A.: GENFIT Reports First Quarter 2025 Financial InformationMay 23, 2025 | finanznachrichten.deGENFIT Reports First Quarter 2025 Financial InformationMay 22, 2025 | globenewswire.comGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyMay 20, 2025 | globenewswire.comGENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 15, 2025 | finanznachrichten.deGENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 14, 2025 | globenewswire.comGenfit: Iqirvo's Success Can't Outweigh ACLF Pipeline RisksMay 12, 2025 | seekingalpha.comGENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory DocumentsMay 7, 2025 | globenewswire.comGENFIT to Present Latest ACLF Research at EASL Congress 2025May 5, 2025 | globenewswire.comGENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-FApril 29, 2025 | globenewswire.comGENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025April 28, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 25, 2025 | finanznachrichten.deGENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 24, 2025 | globenewswire.comGENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 20, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for WeekMarch 14, 2025 | msn.comRoyalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEsMarch 10, 2025 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2024February 27, 2025 | globenewswire.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks3 Notable Stocks Just Split: Which One Could Be the Big Winner?By Leo Miller | June 26, 2025View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?Lululemon, UNH, Enphase: Bad News, Good Opportunity?By Thomas Hughes | June 17, 2025View Lululemon, UNH, Enphase: Bad News, Good Opportunity?Silver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?FRE, EI, and GNFT Company DescriptionsFremont Gold CVE:FREC$0.15 0.00 (0.00%) As of 11/5/2024Fremont Gold Ltd., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral properties in the United States and Canada. The company explores for gold and copper deposit. The company was formerly known as Palisades Ventures Inc. and changed its name to Fremont Gold Ltd. in June 2017. Fremont Gold Ltd. was incorporated in 2007 and is headquartered in Vancouver, Canada.GENFIT NASDAQ:GNFT$3.61 -0.23 (-5.99%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$2.76 -0.85 (-23.55%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
